LIXTE pivots from biotech to AI energy infrastructure; Stuart Porter joins board

LIXTE Biotechnology is transforming into an AI energy infrastructure equipment and services company to address power demands of hyperscale data centers, while seeking a strategic buyer for its cancer-focused pharmaceutical operations. The shift positions the company to capitalize on a projected 224-gigawatt increase in North American electricity demand over the next decade driven by AI expansion.